Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study

Xiaocong Li Marston(Shanghai Open University), Martin Unverdorben(Daiichi Sankyo (United States)), X Ye(Daiichi Sankyo (United States)), Xīn Gào(Qingdao University), Yu‐Chen Yeh(Abt Global (United States)), R Wang(Daiichi Sankyo (United States)), Lisa Zimmermann(University Medical Center Freiburg)
European Heart Journal
November 1, 2020
Cited by 4


Related Papers